BACKGROUND: Although improved quality of life is one of the primary aims of catheter ablation for paroxysmal atrial fibrillation, there is a paucity of published data on this topic. OBJECTIVES: The purpose of this study was to determine the effect of curative catheter ablation on the quality of life of patients with symptomatic, drug-refractory paroxysmal atrial fibrillation. METHODS: This was a prospective nonrandomized study of 63 consecutively enrolled patients (49 men and 14 women, age 56 +/- 7 years). Patients were excluded from the study if they had significant structural heart disease. The ablation strategy consisted of systematic isolation of all pulmonary veins, followed by limited linear ablation in the atria comprising left isthmus ablation (between the left inferior pulmonary vein and lateral mitral annulus) and cavotricuspid isthmus ablation. Patients completed quality-of-life questionnaires comprising the SF-36 and Symptom Checklist at baseline and 3 and 12 months following ablation. RESULTS: Fifty-four patients (86%) were free of symptomatic recurrence at 12-month follow-up. Successful ablation resulted in a significant improvement of all eight subscales of the SF-36 and of symptom frequency and severity scores of the symptom checklist at 3 months. This improvement was maintained at 12 months. CONCLUSIONS: Combined pulmonary vein isolation and linear atrial ablation has a high success rate for cure of paroxysmal atrial fibrillation. Successful curative catheter ablation of paroxysmal atrial fibrillation significantly and persistently improved quality of life during long-term follow-up. This improvement in quality of life was accompanied by a significant reduction in arrhythmia symptom frequency and severity.
BACKGROUND: Although improved quality of life is one of the primary aims of catheter ablation for paroxysmal atrial fibrillation, there is a paucity of published data on this topic. OBJECTIVES: The purpose of this study was to determine the effect of curative catheter ablation on the quality of life of patients with symptomatic, drug-refractory paroxysmal atrial fibrillation. METHODS: This was a prospective nonrandomized study of 63 consecutively enrolled patients (49 men and 14 women, age 56 +/- 7 years). Patients were excluded from the study if they had significant structural heart disease. The ablation strategy consisted of systematic isolation of all pulmonary veins, followed by limited linear ablation in the atria comprising left isthmus ablation (between the left inferior pulmonary vein and lateral mitral annulus) and cavotricuspid isthmus ablation. Patients completed quality-of-life questionnaires comprising the SF-36 and Symptom Checklist at baseline and 3 and 12 months following ablation. RESULTS: Fifty-four patients (86%) were free of symptomatic recurrence at 12-month follow-up. Successful ablation resulted in a significant improvement of all eight subscales of the SF-36 and of symptom frequency and severity scores of the symptom checklist at 3 months. This improvement was maintained at 12 months. CONCLUSIONS: Combined pulmonary vein isolation and linear atrial ablation has a high success rate for cure of paroxysmal atrial fibrillation. Successful curative catheter ablation of paroxysmal atrial fibrillation significantly and persistently improved quality of life during long-term follow-up. This improvement in quality of life was accompanied by a significant reduction in arrhythmia symptom frequency and severity.
Authors: Karuna Chilukuri; Daniel Scherr; Darshan Dalal; Alan Cheng; David Spragg; Saman Nazarian; Bernadette D Barcelon; Joseph E Marine; Hugh Calkins; Charles A Henrikson Journal: J Interv Card Electrophysiol Date: 2011-05-26 Impact factor: 1.900
Authors: Jorge Gonzalez; Laurent Macle; Marc W Deyell; Matthew T Bennett; Marc Dubuc; Katia Dyrda; Peter G Guerra; Paul Khairy; Blandine Mondesert; Léna Rivard; Denis Roy; Mario Talajic; Bernard Thibault; Jason G Andrade Journal: J Atr Fibrillation Date: 2014-04-30
Authors: Axel Meissner; Irini Stifoudi; Peter Weismüller; Max-Olav Schrage; Petra Maagh; Martin Christ; Thomas Butz; Hans-Joachim Trappe; Gunnar Plehn Journal: Int J Med Sci Date: 2009-01-11 Impact factor: 3.738